CCND1 is altered in 0.27% of meningioma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CCND2 is altered in 0.27% of meningioma patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDKN2A is altered in 5.47% of meningioma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDKN2B is altered in 4.89% of meningioma patients [2].

CDKN2B is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2B status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDKN2C is altered in 2.14% of meningioma patients [2].

CDKN2C is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

EGFR is altered in 0.76% of meningioma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and meningioma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and meningioma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is altered in 1.32% of meningioma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and meningioma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYCN is altered in 0.53% of meningioma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and meningioma as inclusion criteria, 1 is no phase specified (1 open) [3].

NF2 is altered in 42.22% of meningioma patients [2].

NF2 is an inclusion eligibility criterion in 3 clinical trials for meningioma, of which 1 is open and 2 are closed. Of the trials that contain NF2 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (0 open) [3].

SMO is altered in 4.87% of meningioma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for meningioma, of which 0 are open and 1 is closed. Of the trial that contains SMO status and meningioma as inclusion criteria, 1 is phase 2 (0 open) [3].